To evaluate the efficacy of the conditioning regimen with cyclophosphamide, fludarabine, and
antithymocyte globulin (CyFluATG) for allogeneic hematopoietic cell transplantation (HCT) in
patients with lower risk myelodysplastic syndrome (MDS). The efficacy of the treatment will
be measured in terms of engraftment and non-relapse mortality (NRM).